Literature DB >> 27112389

Prostate cancer: Towards effective combination of ADT and immunotherapy.

Clemens Thoma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27112389     DOI： 10.1038/nrurol.2016.80

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse.

Authors:  Yang Pu; Meng Xu; Yong Liang; Kaiting Yang; Yajun Guo; Xuanming Yang; Yang-Xin Fu
Journal:  Sci Transl Med       Date:  2016-04-06       Impact factor: 17.956
  1 in total
  2 in total

Review 1.  Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance.

Authors:  Rongbin Ge; Zongwei Wang; Liang Cheng
Journal:  NPJ Precis Oncol       Date:  2022-05-04

2.  Current and emerging trends in prostate cancer immunotherapy.

Authors:  Adam Schatz; Badar M Mian
Journal:  Asian J Androl       Date:  2017-11-24       Impact factor: 3.285
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.